» Research » Research Projects » Research MICROBIOTA

Combatting Disorders of Adaptive Immunity with Systems Medicine

EU COSMIC Financing: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158.
Duration: January 2018 – December 2021
Web: https://cosmic-h2020.eu



Consortium description

COSMIC brings together 10 beneficiaries from 9 different European countries with industrial and academic backgrounds:

  • Academic Medical Center, AMC, NL-Coordinator
    • Bioinformatics Laboratory, Prof. dr. A.H.C. van Kampen
    • Rheumatology and clinical immunology, Dr. N. de Vries
    • Dept. of Pathology, Dr. J.E.J. Guikema
  • Research Centre Inria, INRIA, FR, DRACULA team Dr. O. Gandrillon Dr. F. Crauste
  • Karolinska institute, KI, SE, Dept. of Medical Biochemistry and Biophysics Prof. dr. R. Holmdahl
  • Babraham Institute, BI, UK, Lymphocyte signalling and development Dr. M. Turner
  • FIRC Institute of Molecular Oncology, IFOM, IT, Genetics of B cells and lymphomas Dr. S. Casola
  • Anaxomics Biotech S.L, ANX, ES Expertise: systems biology, Dr. J. Farres
  • Redoxis AB, RDX, SE, Expertise: pre-clinical models of autoimmune disease, Dr. M. Hultqvist Hopkins
  • Helmholtz Centre for Infection Research, HZI, DE, Systems Immunology Prof. dr. M. Meyer- Hermann
  • IBM, IBM, CH, Expertise: systems biology Dr. María Rodríguez Martínez
  • Centre for Research and Technology Hellas, CERTH, EL Institute of Applied Biosciences, Dr. K. Stamatopoulos

Project Description

COSMIC establishes state-of-the art experimental and computational approaches to elucidate the cellular and molecular mechanisms that control the normal germinal centre reaction and its role in B-cell lymphoma (BCL; WP3) and rheumatoid arthritis (RA; WP4). Computational disease models (WP5) will be developed to complement and guide the experimental work. Through the combination of these approaches we also aim at the identification of putative diagnostic markers and/or drug targets for BCL and RA. COSMIC established a unique cross-fertilization between the oncology and auto-immunity research fields